Anti-TREM2 antibodies and methods of use thereof

US11124567B2 · kind B2 · utility

Assignee

• DENALI THERAPEUTICS INC. · US

Inventors

• Mark S. Dennis · South San Francisco, US
• Zhenyu Gu · Cupertino, US
• Mihalis Kariolis · South San Francisco, US
• Cathal S. Mahon · San Francisco, US
• Kathryn M. Monroe · South San Francisco, US
• Joshua I. Park · Village of La Jolla, US
• Rachel Prorok · South San Francisco, US
• Adam P. Silverman · South San Francisco, US
• Bettina Van Lengerich · South San Francisco, US

Key dates

• Filing date: Jan 15, 2021
• Grant date: Sep 21, 2021
• Expiry date: Jan 15, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.